AnteoTech Ltd (ASX: ADO) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Anteotech Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AnteoTech Ltd (ASX: ADO)
Latest News

Share Gainers
Why these 2 ASX All Ordinaries shares are surging more than 20% today

Healthcare Shares
Why the AnteoTech share price is rocketing 33% today

Healthcare Shares
Here’s why the Anteotech (ASX:ADO) share price is leaping 6% today

Healthcare Shares
The AnteoTech (ASX:ADO) share price RAT-tles down 8% following TGA update

Share Fallers
Why AnteoTech, ASX, CIMIC, and Temple & Webster shares are dropping

Healthcare Shares
Rats! How have AnteoTech (ASX:ADO) shares already gained 30% in February?

Coronavirus News
Why are ASX COVID test shares climbing today?

Healthcare Shares
AnteoTech (ASX:AD) share price surges 15% as COVID-19 RAT race continues
ADO ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About AnteoTech Ltd
AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its keys areas are Energy and Life ScienceDivision. The company is developing four products named AnteoCoat, AnteoX, AnteoBind, and AnteoRelease, all of these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the Anteo Intellectual property.
ADO Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
20 May 2022 | $0.12 | $0.00 | 0.00% | 4,471,990 | $0.12 | $0.12 | $0.11 |
19 May 2022 | $0.12 | $-0.02 | -15.38% | 4,813,431 | $0.12 | $0.13 | $0.11 |
18 May 2022 | $0.13 | $0.04 | 42.55% | 21,702,289 | $0.12 | $0.15 | $0.11 |
17 May 2022 | $0.09 | $0.00 | 0.00% | 983,531 | $0.09 | $0.10 | $0.09 |
16 May 2022 | $0.09 | $0.00 | 0.00% | 1,253,492 | $0.10 | $0.10 | $0.09 |
13 May 2022 | $0.10 | $0.00 | 0.00% | 668,313 | $0.09 | $0.10 | $0.09 |
12 May 2022 | $0.09 | $0.00 | 0.00% | 1,842,160 | $0.09 | $0.10 | $0.09 |
11 May 2022 | $0.09 | $0.00 | 0.00% | 4,852,843 | $0.09 | $0.10 | $0.09 |
10 May 2022 | $0.09 | $0.00 | 0.00% | 8,737,227 | $0.09 | $0.10 | $0.09 |
09 May 2022 | $0.10 | $-0.01 | -9.52% | 6,803,794 | $0.10 | $0.11 | $0.10 |
06 May 2022 | $0.11 | $0.00 | 0.00% | 2,708,258 | $0.11 | $0.11 | $0.10 |
05 May 2022 | $0.11 | $0.00 | 0.00% | 3,145,859 | $0.11 | $0.11 | $0.11 |
04 May 2022 | $0.11 | $-0.01 | -9.09% | 7,571,962 | $0.11 | $0.11 | $0.10 |
03 May 2022 | $0.11 | $-0.01 | -8.70% | 3,438,781 | $0.11 | $0.12 | $0.11 |
02 May 2022 | $0.12 | $0.00 | 0.00% | 4,679,181 | $0.12 | $0.12 | $0.11 |
29 Apr 2022 | $0.12 | $0.00 | 0.00% | 2,124,327 | $0.12 | $0.12 | $0.12 |
28 Apr 2022 | $0.12 | $0.00 | 0.00% | 726,790 | $0.12 | $0.12 | $0.12 |
27 Apr 2022 | $0.12 | $0.00 | 0.00% | 1,621,743 | $0.12 | $0.13 | $0.12 |
26 Apr 2022 | $0.12 | $-0.02 | -15.38% | 2,797,084 | $0.13 | $0.13 | $0.12 |
22 Apr 2022 | $0.13 | $0.00 | 0.00% | 3,487,942 | $0.13 | $0.14 | $0.12 |
21 Apr 2022 | $0.13 | $-0.01 | -7.14% | 5,860,615 | $0.14 | $0.15 | $0.13 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
09 May 2022 | Ewen Crouch | Buy | 250 | $27,675 |
On-market trade.
|
03 May 2022 | Geoffrey Cumming | Sell | 2 | $220,000 |
On-market trade.
|
23 Dec 2021 | Geoffrey Cumming | Sell | 500 | $108,000 |
On-market trade.
|
17 Sep 2021 | Glenda McLoughlin | Buy | 250 | $58,750 |
On-market trade.
|
02 Aug 2021 | Geoffrey Cumming | Sell | 500 | $112,500 |
On-market trade.
|
25 May 2021 | Geoffrey Cumming | Buy | 17 | $4,515 |
Participation in share purchase plan.
|
25 May 2021 | Geoffrey Cumming | Sell | 17 | $4,515 |
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
|
25 May 2021 | John (Jack) Hamilton | Sell | 24 | $6,257 |
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
|
25 May 2021 | John (Jack) Hamilton | Buy | 24 | $6,257 |
Participation in share purchase plan.
|
25 May 2021 | Christopher Parker | Sell | 17 | $4,515 |
As advised by the company. Withdrawal of SPP application (at $0.26 per share)
|
25 May 2021 | Christopher Parker | Buy | 17 | $4,515 |
Participation in share purchase plan.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Katherine Leslie Woodthorpe | Non-Executive Director | Sep 2021 |
Dr Woodthorpe is an experienced Chair and Non-Executive Director serving for 20 years on the boards of a range of organizations including listed entities, government boards and for purpose organizations. She has experience working in a range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. Katherine also has knowledge of the private equity and venture capital industries in the financial sector as well as working closely with superannuation funds on their alternative investments in the private equity space. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Prior to AVCAL, she held a range of management and board positions, in Australia and overseas. Katherine commenced her career initially as a chemist then moved to sales of specialised laboratory equipment into the medical and oil, gas and petrochemical sectors covering the geographies of Europe, Asia and the Middle East before locating permanently to Australia in 1988. Dr Woodthorpe, amongst several positions, is a Non-Executive Director of the Olivia Newton John Cancer Research Institute, Bioplatforms Australia Ltd and Vast Solar Pty Ltd.
|
Dr Geoffrey James Cumming | Non-Executive Director | Apr 2009 |
Dr Cumming has over 20 years experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre, where he transformed a loss making business to one achieving over 30% compound annual growth over a four year period and the highest profitability levels in Roches global organisation. He was also Managing Director and CEO of an Australian based biotechnology company commercialising a range of products in cancer diagnosis and treatment. During his tenure he was responsible for taking research from Sydney University through to product registration. This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. Geoffrey is a Non-Executive Director of Multiple Sclerosis Research Australia, a not-for profit organisation.
|
Ms Glenda McLoughlin | Non-Executive Director | Sep 2021 |
Ms McLaughlin is an experienced Non-Executive Director with over 25 years' experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Glenda co-founded listed Australian gas company Metgasco Ltd, where she was Executive Director and Chief Financial Officer for eight years. Ms McLoughlin currently holds the positions of Non-Executive Director with Senex Energy Ltd where she chairs the Audit and Risk Committee and is Chair of SCEGGS Redlands. Ms McLoughlin will also Chair of AnteoTech's Risk Committee.
|
Mr Richard Shubrick Martin | Non-Executive Director | Sep 2005 |
Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
|
Mr Ewen Graham Wolseley Crouch | Non-Executive ChairmanNon-Executive Director | Apr 2022 |
Mr Crouch is currently Chairman of Corporate Travel Management Limited (ASX: CTD) and serves on the Boards of Bluescope Steel Limited (ASX: BSL) and respected Australian non-profit organisation Jawun. From 1988-2103 Mr Crouch was a partner at Allens. He served as Chairman of Partners for 4 years and held a number of practice leadership and management roles, including 11 years of service on the firm's board. He was previously a Director of Westpac Banking Corporation Limited (ASX: WBC), a director of Mission Australia including seven years as Chairman, a member of the Takeovers Panel, a member of the Commonwealth Remuneration Tribunal and a director of Sydney Symphony Orchestra. His board experience and corporate knowledge, together with his governance, legal and international transaction experience complements well the skillset of the current Board of AnteoTech.
|
Mr Christopher Parker | Executive Director | Nov 2019 |
Mr Parker has 30 years plus of experience in both domestic and international life sciences sector mainly with Roche Diagnostics ("Roche"), an internationally renowned pharmaceutical and diagnostics company. In his final role with Roche, before retiring in late 2017, he was Managing Director for UK & Ireland and Management Centre for European Agents where he had responsibility for all diagnostic products in the Roche portfolio. Prior to this he held various roles in general management, marketing and business development in Canada, Asia and Australia targeting the centralised laboratory, decentralised point-of-care (POC), molecular diagnostics and applied sciences markets. Mr Parker was a previous CEO for AnteoTech between April 2018 and May 2019 and then an Executive Director until November 2019.
|
Mr Duncan Patrick Cornish | Chief Financial OfficerCompany Secretary | Feb 2019 |
-
|
Mr Derek Thomson | Chief Executive Officer | Aug 2019 |
-
|
Derek Thomson | Chief Executive Officer |
-
|
|
Duncan Patrick Cornish | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Levenson Investments Pty Ltd <Levenson Investment A/C> | 109,315,332 | 5.55% |
First Cape Management Pty Ltd | 55,346,154 | 2.81% |
Marcolongo Nominees Pty Ltd <Marcolongo Super Fund A/C> | 53,439,928 | 2.71% |
Addison Lake Quality Hire Pty Limited | 33,048,603 | 1.68% |
Fossil Super Pty Ltd <Fossil Fund A/C> | 32,459,231 | 1.65% |
Jackjen Pty Ltd <J A Hamilton Super Fund A/C> | 30,018,593 | 1.52% |
Bond Street Custodians Limited <Antsm1 - D67076 A/C> | 29,130,249 | 1.48% |
Computer Visions Pty Ltd <Visionary Invests S/F A/C> | 22,132,994 | 1.12% |
BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient DRP> | 21,599,216 | 1.10% |
Mr Derek Thomson | 21,580,554 | 1.10% |
Marcolongo Nominees Pty Ltd <Marcolongo Family A/C> | 20,134,578 | 1.02% |
Mrs Mary Curtis | 18,120,900 | 0.92% |
Mr Peter Frederick Kemmis | 17,198,314 | 0.87% |
Citicorp Nominees Pty Limited | 17,083,422 | 0.87% |
Awo & Cao Investments Pty Ltd <Awo & Cao Family S/F A/C> | 15,983,571 | 0.81% |
Stydon Capital Pty Ltd | 15,536,780 | 0.79% |
Terry & Linden Deavin Super Pty Ltd <T & L Deavin Sf A/C> | 14,600,000 | 0.74% |
Austcorp No 190 Pty Ltd | 14,381,945 | 0.73% |
Mr Anthony William Olding & Mrs Caroline Anne Olding | 14,091,375 | 0.72% |
Mr Philip Michael Deavin & Mrs Chimene Maree Deavin | 13,260,000 | 0.67% |